4 Diagnostic challenges in acromegaly: a case-based review

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue SUPPL. 1, 2009, Pages

  Bonert, Vivien ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

acromegaly; assay; diagnosis; growth; hormone (GH); insulin like growth factor 1 (IGF 1)

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C; HUMAN GROWTH HORMONE;

ACROMEGALY; AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH HORMONE BLOOD LEVEL; HUMAN; IMMUNORADIOMETRIC ASSAY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; OVERALL SURVIVAL; PHYSICAL EXAMINATION; QUALITY OF LIFE; RADIOIMMUNOASSAY; REFERENCE VALUE; TRANSSPHENOIDAL SURGERY; ADENOMA; DIFFERENTIAL DIAGNOSIS; DIZZINESS; ENDOCRINE SYSTEM EXAMINATION; HEADACHE; HYPOPHYSIS TUMOR; REVIEW; STANDARD;

ACROMEGALY; ADENOMA; AGED; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC TECHNIQUES, ENDOCRINE; DIZZINESS; HEADACHE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; PITUITARY NEOPLASMS;

EID: 73149088139     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-690X(09)70005-3     Document Type: Article

References (32)

1. Alexander L., Appleton D., Hall R., et al. Epidemiology of acromegaly in the Newcastle region. Clinical Endocrinology (Oxford) 12 (1980) 71-79
2. Bengtsson B.A., Edén S., Ernest I., et al. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Medica Scandinavica 223 (1988) 327-335
3. Ritchie C.M., Atkinson A.B., Kennedy A.L., et al. Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Medical Journal 59 (1990) 5562
4. Etxabe J., Gaztambide S., Latorre P., et al. Acromegaly: an epidemiological study. Journal of Endocrinological Investigation 16 (1993) 181-187
5. Holdaway I.M., and Rajasoorya C. Epidemiology of acromegaly. Pituitary 2 (1999) 29-41
6. Daly A.F., Petrossians P., and Beckers A. An overview of the epidemiology and genetics of acromegaly. Journal of Endocrinological Investigation 28 Suppl. (2005) 67-69
7. Nabarro J.D. Acromegaly. Clinical Endocrinology (Oxford) 26 (1987) 481-512
8. Nachtigall L., Delgado A., Swearingen B., et al. Changing patterns in diagnosis and therapy of acromegaly over two decades. Journal of Clinical Endocrinology and Metabolism 93 (2008) 2035-2041
9. Chanson P., and Salenave S. Acromegaly. Orphanet Journal of Rare Diseases 3 (2008) 17
10. Chanson P., Timsit J., Masquet C., et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Annals of Internal Medicine 133 (1990) 197-201
11. Lioté F., and Orcel P. Osteoarticular disorders of endocrine origin. Baillière's Best Practice & Research Clinical Rheumatology 14 (2000) 251-276
12. Melmed S., Colao A., Barkan A., et al. Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism 94 (2009) 1509-1517
13. Colao A., Ferone D., Marzullo P., et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 25 (2004) 102-152
14. Vitale G., Pivonello R., Lombardi G., et al. Cardiovascular complications in acromegaly. Minerva Endocrinologica 29 (2004) 77-88
15. Clemmons D.R., Van Wyk J.J., Ridgway E.C., et al. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. The New England Journal of Medicine 301 (1979) 1138-1142
16. Dimaraki E.V., Jaffe C.A., DeMott-Friberg R., et al. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. Journal of Clinical Endocrinology and Metabolism 87 (2002) 3537-3542
17. Daughaday W.H., Starkey R.H., Saltman S., et al. Characterization of serum growth hormone (GH) and insulin-like growth factor I in active acromegaly with minimal elevation of serum GH. Journal of Clinical Endocrinology and Metabolism 65 (1987) 617-623
18. Rieu M., Girard F., Bricaire H., et al. The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly. Journal of Clinical Endocrinology and Metabolism 55 (1982) 147-153
19. Sakharova A.A., Dimaraki E.V., Chandler W.F., et al. Clinically silent somatotropinomas may be biochemically active. Journal of Clinical Endocrinology and Metabolism 90 (2005) 2117-2121
20. Yamada S., Sano T., Stefaneanu L., et al. Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary. Journal of Clinical Endocrinology and Metabolism 76 (1993) 352-356
21. Kovacs K., Lloyd R., Horvath E., et al. Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. American Journal of Pathology 134 (1989) 345-353
22. Horvath E., Kovacs K., and Killinger D.W. Silent corticotropic adenomas of the pituitary gland: a histologic, immunocytologic and ultrastructural study. American Journal of Pathology 98 (1980) 617-638
23. Giustina A., Barkan A., Casanueva F.F., et al. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 85 (2000) 526-529
24. Trainer P.J. Acromegaly - consensus, what consensus?. Journal of Clinical Endocrinology and Metabolism 87 (2002) 3534-3536
25. Melmed S., Casanueva F., Cavagnini F., et al. Consensus statement: medical management of acromegaly. European Journal of Endocrinology 153 (2005) 737-740
26. Freda P.U., Reyes C.M., Nuruzzaman A.T., et al. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary 6 (2003) 175-180
27. Freda P.U., Post K.D., Powell J.S., et al. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 post-operative patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 83 (1998) 3808-3816
28. Trainer P.J., Barth J., Sturgeon C., et al. Consensus statement on the standardisation of GH assays. European Journal of Endocrinology 155 (2006) 1-2
29. Pokrajac A., Wark G., Ellis A.R., et al. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clinical Endocrinology (Oxford) 67 (2007) 65-70
30. Arafat A.M., Möhlig M., Weickert M.O., et al. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. Journal of Clinical Endocrinology and Metabolism 93 (2008) 1254-1262
31. Clemmons D.R. IGF-I assays: current assay methodologies and their limitations. Pituitary 10 (2007) 121-128
32. Milani D., Carmichael J.D., Welkowitz J., et al. Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. Journal of Clinical Endocrinology and Metabolism 89 (2004) 2271-2274